...
首页> 外文期刊>Transplantation Proceedings >The clinical outcome of end-stage renal disease patients who return to peritoneal dialysis after renal allograft failure
【24h】

The clinical outcome of end-stage renal disease patients who return to peritoneal dialysis after renal allograft failure

机译:肾移植失败后返回腹膜透析的终末期肾脏病患者的临床结局

获取原文
获取原文并翻译 | 示例

摘要

Background With the increased numbers of kidney transplantations, more patients return to dialysis after graft loss (DAGL). The aim of this study was to investigate the safety and efficacy of peritoneal dialysis (PD) after graft loss compared with transplant-naive PD patients (TN-PD). Method This study was conducted on 715 patients who started PD between 1988 and 2009, including 47 who started PD after allograft loss (DAGL-PD) and 668 in the (TN-PD) group. Result The mean ages were 40.8 ± 10.7 in DAGL-PD group and 51.03 ± 14.20 in TN-PD group (P <.01). The most common cause of end-stage renal disease in DAGL was primary glomerulonephritis (76.6%), but it was diabetes mellitus (38.9%) in the TN-PD group (P <.05). Patient survival rates at 1, 5, and 10 years were not different: 100%, 86%, and 57% versus 91%, 70%, and 62%, respectively. PD survival rate at 1, 5, and 10 years did not show significant differences: 98%, 95%, and 88% versus 95%, 80%, and 66%, respectively. The most common causes of death in both groups were infection (DAGL, 26.7%; TN-PD, 24.5%) followed by cardiovascular disease (DAGL, 20.0%; TN-PD, 19.6%); the distribution of causes did not differ significantly (P >.05). Conclusion The clinical outcomes of PD in DAGL group were comparable with those of TN-PD patients. Therefore, PD could be considered as a dialysis modality for patients who experience allograft failure.
机译:背景技术随着肾脏移植数量的增加,越来越多的患者在移植物丢失(DAGL)后恢复透析。这项研究的目的是研究与初次移植的PD患者(TN-PD)相比,移植物丢失后腹膜透析(PD)的安全性和有效性。方法这项研究针对1988年至2009年间715例开始PD的患者进行,其中47例在同种异体移植丧失(DAGL-PD)后开始PD,而在(TN-PD)组为668例。结果DAGL-PD组平均年龄为40.8±10.7,TN-PD组平均年龄为51.03±14.20(P <.01)。 DAGL中最常见的终末期肾病原因是原发性肾小球肾炎(76.6%),但在TN-PD组中是糖尿病(38.9%)(P <.05)。 1年,5年和10年的患者生存率没有差异:分别为100%,86%和57%,而分别为91%,70%和62%。 1、5和10年的PD生存率没有显着差异:分别为98%,95%和88%,分别为95%,80%和66%。两组中最常见的死亡原因是感染(DAGL,26.7%; TN-PD,24.5%),其次是心血管疾病(DAGL,20.0%; TN-PD,19.6%);原因的分布没有显着差异(P> .05)。结论DAGL组PD的临床结局与TN-PD患者相当。因此,对于同种异体移植失败的患者,PD可被视为透析方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号